Related Experiment Video

Updated: Jun 15, 2026

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade

Tiancheng Liu1, Lisa Y Wu, Joseph K Choi

  • 1Department of Chemistry, Washington State University, Pullman, WA 99164-4630, USA.

International Journal of Oncology
|March 4, 2010
PubMed

Insights

This study developed a targeted photodynamic therapy (PDT) for prostate cancer using a PSMA inhibitor-conjugate. The treatment specifically targets and induces apoptosis in PSMA-positive cancer cells, offering a potential new therapeutic approach.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Photodynamic therapy (PDT) faces limitations in specific photosensitizer delivery to tumors.
  • Prostate-specific membrane antigen (PSMA) is a key biomarker for prostate cancer, making it a promising therapeutic target.
  • Targeted delivery of therapeutic agents can improve treatment efficacy and reduce side effects.

Purpose of the Study:

  • To investigate a PSMA inhibitor-conjugate of pyropheophorbide-a (Ppa-conjugate 2.1) for targeted PDT in prostate cancer.
  • To elucidate the mechanism of cell death induced by Ppa-conjugate 2.1 in prostate cancer cells.
  • To evaluate the specificity and efficacy of Ppa-conjugate 2.1 for PSMA-positive prostate cancer.

Main Methods:

  • Synthesis and characterization of Ppa-conjugate 2.1.
  • Confocal laser scanning microscopy with fluorescence labeling to monitor cellular uptake and effects.
  • Assessment of apoptosis markers including caspase activation (caspase-8, -3, -9), PARP cleavage, and DNA fragmentation.
  • Caspase inhibitor blocking studies to determine the cell death pathway.

Main Results:

  • Ppa-conjugate 2.1 demonstrated specific uptake and induced apoptosis in PSMA-positive LNCaP cells, but not in PSMA-negative PC-3 cells.
  • PDT with Ppa-conjugate 2.1 led to sequential activation of caspase-8, -3, -9, PARP cleavage, and DNA fragmentation.
  • Cleaved beta-actin confirmed the involvement of caspase-3 in the apoptotic process.
  • Caspase inhibitor studies confirmed the critical role of the caspase-8/-3 cascade in Ppa-conjugate 2.1-induced apoptosis.

Conclusions:

  • Ppa-conjugate 2.1 is a PSMA-targeted agent effective in inducing apoptosis in prostate cancer cells via PDT.
  • The mechanism of cell death involves the caspase-8/-3 cascade, highlighting its importance in this targeted therapy.
  • Targeted PDT using PSMA-conjugates represents a promising alternative treatment strategy for prostate cancer.

More Related Videos

An In Vitro Approach to Photodynamic Therapy04:53

An In Vitro Approach to Photodynamic Therapy

Published on: August 17, 2018

Related Concept Videos

The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...